Payment overview · 2025
General Payments
$3,253.68
161 reported records · 20 companies
Healthcare provider profile · identity verified
Khoa Vo, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · MT PLEASANT, SC · NPI 1225094931
Verified facts
What the public records show
CMS Open Payments records show Khoa Vo, MD received $3,253.68 in general payments during 2025 across 161 reported records.
Axsome Therapeutics, Inc. accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Hetlioz, Loreev Xr, Quviviq.
Almatica Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOREEV XR as an associated drug or biological on 9621 records involving 4446 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Loreev Xr by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Auvelity by this doctor in 2024.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Quviviq by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Caplyta by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HETLIOZ as an associated drug or biological on 22380 records involving 6461 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Hetlioz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $439.88 | 13.5% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $325.67 | 10.0% | 24 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $304.74 | 9.4% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $287.05 | 8.8% | 14 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $245.87 | 7.6% | 12 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $226.36 | 7.0% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $213.76 | 6.6% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $204.43 | 6.3% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $166.17 | 5.1% | 10 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $154.26 | 4.7% | 9 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $114.91 | 3.5% | 6 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $107.85 | 3.3% | 5 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $100.67 | 3.1% | 6 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $90.71 | 2.8% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $73.57 | 2.3% | 4 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $69.02 | 2.1% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $67.76 | 2.1% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $29.15 | 0.9% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $18.31 | 0.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $13.54 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,253.68 | 161 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $509.17 | 20 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $439.88 | 19 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $325.67 | 24 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $287.05 | 14 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $287.05 | 14 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $245.87 | 12 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $226.36 | 10 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $213.76 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $166.17 | 10 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $154.26 | 9 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $107.85 | 5 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $100.67 | 6 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $99.77 | 5 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $90.71 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $73.57 | 4 | 2025 |
Source payment records
|
|||||
| EXXUA Normalized: exxua |
Drug | Neos Therapeutics, LP | $69.02 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $67.76 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Onyda XR Normalized: onyda xr |
Drug | Tris Pharma Inc | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| HETLIOZ hetlioz |
2025 | Hetlioz | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOREEV XR loreev xr |
2025 | Loreev Xr | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Almatica Pharma LLC Exact reporting entity; no affiliate inference |
2025 | LOREEV XR open payments reported associated product |
CMS Open Payments — General Payments 9621 supporting records · 4446 recipient NPIs · example record 1209929018 |
Loreev Xr · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | HETLIOZ open payments reported associated product |
CMS Open Payments — General Payments 22380 supporting records · 6461 recipient NPIs · example record 1232940535 |
Hetlioz · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 116 | 14 |
| Alprazolam | Alprazolam | 104 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 95 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 12 |
| Bupropion Xl | Bupropion Hcl | 59 | 16 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Trazodone Hcl | Trazodone Hcl | 37 | 11 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Clozapine | Clozapine | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 23 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Quviviq | Daridorexant Hcl | 15 | suppressed |
| Gabapentin | Gabapentin | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Loreev Xr | Lorazepam | 14 | suppressed |
| Caplyta | Lumateperone Tosylate | 13 | suppressed |
| Metformin Hcl | Metformin Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Hetlioz | Tasimelteon | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,253.68 · 161 records | Axsome Therapeutics, Inc. | APLENZIN, ARISTADA, Auvelity, Azstarys, CAPLYTA, COBENFY, Dyanavel XR, EXXUA, FANAPT, HETLIOZ, INGREZZA, LOREEV XR, LUMRYZ, LYBALVI, Onyda XR, Qelbree, Quviviq, REXULTI, SPRAVATO, TRINTELLIX, VRAYLAR, Xelstrym | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Almatica Pharma LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error